Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESSO 45 | Surgical margins after neoadjuvant therapy versus upfront breast surgery

Antonio Esgueva, MD, PhD, University Hospital of Navarra, Madrid, Spain, discusses two studies examining safer surgical approaches for patients with breast cancer receiving neoadjuvant therapy, demonstrating that such treatment does not increase re-excision rates compared with upfront surgery despite patients presenting with larger, more aggressive tumors. Neoadjuvant therapy itself is not problematic for surgical margins, and no differences in overall survival between groups were also reported after adjusting for confounding factors. This interview took place at the 2026 European Society of Surgical Oncology (ESSO) Annual Meeting in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Both studies are both about the same idea, safely doing less surgery for breast cancer patients when they don’t need it. More and more women now receive neoadjuvant therapy. It shrinks the tumour and that changes how we should operate, both on the breast and in the axilla. Well, neoadjudant therapy lets many women keep their breasts instead of having a mastectomy, But surgeons Patients have worried that after this treatment, the margins are harder to get right, so more patients might get more than a second operation...

Both studies are both about the same idea, safely doing less surgery for breast cancer patients when they don’t need it. More and more women now receive neoadjuvant therapy. It shrinks the tumour and that changes how we should operate, both on the breast and in the axilla. Well, neoadjudant therapy lets many women keep their breasts instead of having a mastectomy, But surgeons Patients have worried that after this treatment, the margins are harder to get right, so more patients might get more than a second operation. in experience, no. We studied more than 1 ,000 patients who had breast cancer surgery at Clinica Universidad de Navarra. The neoadjuvant patients had larger, more aggressive tumours, and even so, their accretion rates were the same, 9 .6 % with upfront surgery and 8 .9 % after neoadjudant therapy. Well, the tumour itself, specifically when it’s multifocal or multicentric. That was the only dependent factor with almost three times the risk of a second surgery. So the message for surgeons is that neoadjuvant therapy is not the problem. Multifocal and multicentric disease is where we need to plan most carefully. After adjusting for confounding factors, such as tumour size, subtype and nodal sediments, we found no differences in recurrence or offline survival between the two groups. Local-regional recurrence was about 2 .5 % in both. I should be CLEAR, though, that our mean follow-up is only 30 months, so we need longer follow-ups to CONFIRM this.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.